» Articles » PMID: 30208119

Identification of MMP28 As a Biomarker for the Differential Diagnosis of Idiopathic Pulmonary Fibrosis

Overview
Journal PLoS One
Date 2018 Sep 13
PMID 30208119
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Objective: Idiopathic Pulmonary Fibrosis (IPF) is a progressive disease of unknown etiology. The diagnosis is based on the identification of a pattern of usual interstitial pneumonia either by high resolution computed tomography and/or histology. However, a similar pattern can be observed in other fibrotic lung disorders, and precise diagnosis remains challenging. Studies on biomarkers contributing to the differential diagnosis are scanty, and still in an exploratory phase. Our aim was to evaluate matrix metalloproteinase (MMP)-28, which has been implicated in abnormal wound healing, as a biomarker for distinguishing IPF from fibrotic non-IPF patients.

Methods: The cell localization of MMP28 in lungs was examined by immunohistochemistry and its serum concentration was measured by ELISA in two different populations. The derivation cohort included 82 IPF and 69 fibrotic non-IPF patients. The validation cohort involved 42 IPF and 41 fibrotic non-IPF patients.

Results: MMP28 was detected mainly in IPF lungs and localized in epithelial cells. In both cohorts, serum concentrations of MMP28 were significantly higher in IPF versus non-IPF (mostly with lung fibrosis associated to autoimmune diseases and chronic hypersensitivity pneumonitis) and healthy controls (ANOVA, p<0.0001). The AUC of the derivation cohort was 0.718 (95%CI, 0.635-0.800). With a cutoff point of 4.5 ng/mL, OR was 5.32 (95%CI, 2.55-11.46), and sensitivity and specificity of 70.9% and 69% respectively. The AUC of the validation cohort was 0.690 (95%CI, 0.581-0.798), OR 4.57 (95%CI, 1.76-12.04), and sensitivity and specificity of 69.6% and 66.7%. Interestingly, we found that IPF patients with definite UIP pattern on HRCT showed higher serum concentrations of MMP28 than non-IPF patients with the same pattern (7.8±4.4 versus 4.9±4.4; p = 0.04). By contrast, no differences were observed when IPF with possible UIP-pattern were compared (4.7±3.2 versus 3.9±3.0; p = 0.43).

Conclusion: These findings indicate that MMP28 might be a useful biomarker to improve the diagnostic certainty of IPF.

Citing Articles

Diagnosis of Fibrotic Hypersensitivity Pneumonitis: Is There a Role for Biomarkers?.

Pereira J, Fernandes V, Alfaro T, Freitas S, Cordeiro C Life (Basel). 2023; 13(2).

PMID: 36836922 PMC: 9966605. DOI: 10.3390/life13020565.


Detection of interstitial pneumonia with autoimmune features and idiopathic pulmonary fibrosis are enhanced by involvement of matrix metalloproteinases levels and clinical diagnosis.

Liu M, Xue M, Zhang T, Lin R, Guo B, Chen Y J Clin Lab Anal. 2022; 36(11):e24734.

PMID: 36250225 PMC: 9701863. DOI: 10.1002/jcla.24734.


Syndrome of Combined Pulmonary Fibrosis and Emphysema: An Official ATS/ERS/JRS/ALAT Research Statement.

Cottin V, Selman M, Inoue Y, Wong A, Corte T, Flaherty K Am J Respir Crit Care Med. 2022; 206(4):e7-e41.

PMID: 35969190 PMC: 7615200. DOI: 10.1164/rccm.202206-1041ST.


Matrix Metalloproteinases and Their Inhibitors in Pulmonary Fibrosis: EMMPRIN/CD147 Comes into Play.

Chulia-Peris L, Carreres-Rey C, Gabasa M, Alcaraz J, Carretero J, Pereda J Int J Mol Sci. 2022; 23(13).

PMID: 35805895 PMC: 9267107. DOI: 10.3390/ijms23136894.


S100A9/CD163 expression profiles in classical monocytes as biomarkers to discriminate idiopathic pulmonary fibrosis from idiopathic nonspecific interstitial pneumonia.

Yamashita M, Utsumi Y, Nagashima H, Nitanai H, Yamauchi K Sci Rep. 2021; 11(1):12135.

PMID: 34108546 PMC: 8190107. DOI: 10.1038/s41598-021-91407-9.


References
1.
Liu C, Shen D, Zhu K, Tang J, Wang X, Zhang L . Characterization of interleukin-33 and matrix metalloproteinase-28 in serum and their association with disease severity in patients with coronary heart disease. Coron Artery Dis. 2014; 25(6):498-504. DOI: 10.1097/MCA.0000000000000117. View

2.
Ley B, Brown K, Collard H . Molecular biomarkers in idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2014; 307(9):L681-91. PMC: 4280147. DOI: 10.1152/ajplung.00014.2014. View

3.
Rosas I, Richards T, Konishi K, Zhang Y, Gibson K, Lokshin A . MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med. 2008; 5(4):e93. PMC: 2346504. DOI: 10.1371/journal.pmed.0050093. View

4.
Borensztajn K, Crestani B, Kolb M . Idiopathic pulmonary fibrosis: from epithelial injury to biomarkers--insights from the bench side. Respiration. 2013; 86(6):441-52. DOI: 10.1159/000357598. View

5.
King Jr T, Bradford W, Castro-Bernardini S, Fagan E, Glaspole I, Glassberg M . A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370(22):2083-92. DOI: 10.1056/NEJMoa1402582. View